DETECTION OF SEVERITY OF THYROID CANCER USING VAN KOSSA STAIN IN IRAQI PATIENTS
Downloads
Objective: To determine the severity of papillary thyroid cancer spread within the tissue using Van kossa stain as a tissue marker indicating the presence of calcifications within the tissue, as well as to estimate thyroglobulin and antithyroglobulin in the serum of cancer patients. Method: For this purpose, tissues have been taken from 50 patients samples with thyroid cancer and 30 samples from healthy individuals as a control group. fallowed by stain with Van kossa stain, for estimating the percentage of calcification within cells. The percentage of thyroglobulin and anti-thyroglobulin in the blood serum of patients was also measured. Results: The results varied; concerning age and sex, similar percentages were recorded for both genders, which were included in the study since no significant difference was found between them. As for age groups, the group with the highest recorded incidence was the age of 50 and above, where a significant difference was found between this age group and the other groups. Regarding the clinical spread of the disease, papillary thyroid cancer patients recorded a score of 3 higher than the rest, and the results showed a significant difference between them and the other groups. Regarding the presence of Psamomma bodies, smaller numbers were recorded within the tissue than in the other groups. The results of estimating thyroglobulin and anti-thyroglobulin in cancer patients showed a clear increase in both levels as compared to healthy controls. Novelty: The results demonstrated the role of Van kossa stain as a marker for calcifications in the tissues of the thyroid gland affected by papillary thyroid cancer, as different numbers were recorded according to the severity of the disease. We also found a significant increase in the levels of Anti Tg and Tg, which gave a close correlation with the severity of the disease and its recurrence within the human body.
Wells SA. Progress in endocrine neoplasia. Clinical Cancer Research. 2016;22(20):4981-4988. doi:10.1158/1078-0432.ccr-16-0384
Morris LGT, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885-891. doi:10.1089/thy.2013.0045
Tang Z, Zhang J, Zhou Q, Xu S, Cai Z, Jiang G. Thyroid Cancer “Epidemic”: a Socio-Environmental health problem needs collaborative efforts. Environmental Science & Technology. 2020;54(7):3725-3727. doi:10.1021/acs.est.0c00852
Kruger E, Toraih EA, Hussein MH, et al. Thyroid Carcinoma: A review for 25 years of environmental risk factors studies. Cancers. 2022;14(24):6172. doi:10.3390/cancers14246172
Crnčić TB. Risk factors for thyroid cancer: What do we know so far? Acta Clinica Croatica. 2020;59(Suppl 1):66-72. doi:10.20471/acc.2020.59.s1.08
Cai M, Gou J. Symptoms and negative emotions in patients with advanced thyroid cancer: a prospective cross-sectional study. BMC Cancer. 2024;24(1):1418. doi:10.1186/s12885-024-13169-7
Lincango-Naranjo E, Solis-Pazmino P, Kawkgi OE, et al. Triggers of thyroid cancer diagnosis: a systematic review and meta-analysis. Endocrine. 2021;72(3):644-659. doi:10.1007/s12020-020-02588-8
Zhang J, Xu S. High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks. Cell Death Discovery. 2024;10(1):378. doi:10.1038/s41420-024-02157-2
Weller S, Chu C, Lam AKY. Assessing the rise in papillary thyroid cancer incidence: A 38-Year Australian study investigating WHO classification influence. Journal of Epidemiology and Global Health. 2025;15(1):9. doi:10.1007/s44197-025-00354-5
Verburg FA, Van Santen H, Luster M. Pediatric papillary thyroid cancer: current management challenges. OncoTargets and Therapy. 2016;Volume 10:165-175. doi:10.2147/ott.s100512
Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The Most Commonly Occurring Papillary Thyroid Cancer in the United States Is Now a Microcarcinoma in a Patient Older than 45 Years. Thyroid. 2011;21(3):231-236. doi:10.1089/thy.2010.0137
Lee JS, Lee JS, Yun HJ, et al. Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm. The Journal of Clinical Endocrinology & Metabolism. 2022;108(6):1370-1375. doi:10.1210/clinem/dgac739
Maksimovic S, Jakovljevic B, Gojkovic Z. Lymph Node Metastases Papillary Thyroid Carcinoma and their Importance in Recurrence of Disease. Medical Archives. 2018;72(2):108. doi:10.5455/medarh.2018.72.108-111
Pacini F, Castagna MG. Approach to and treatment of differentiated thyroid carcinoma. Medical Clinics of North America. 2012;96(2):369-383. doi:10.1016/j.mcna.2012.01.002
Giovanella L, D’Aurizio F, Ovčariček PP, Görges R. Diagnostic, theranostic and prognostic value of thyroglobulin in thyroid cancer. Journal of Clinical Medicine. 2024;13(9):2463. doi:10.3390/jcm13092463
Lin JD. Thyroglobulin and human thyroid cancer. Clinica Chimica Acta. 2007;388(1-2):15-21. doi:10.1016/j.cca.2007.11.002
Kóssa, G., 1901. Über die im Organismus künstlich erzeugbaren Verkalkungen.
Klein, U., 2003. Experiments, models, paper tools: Cultures of organic chemistry in the nineteenth century. Stanford University Press.
Meloan SN, Puchtler H. Chemical Mechanisms of Staining Methods: Von Kossa’s Technique: What von Kossa Really Wrote and a Modified Reaction for Selective Demonstration of Inorganic Phosphates. Journal of Histotechnology. 1985;8(1):11-13. doi:10.1179/his.1985.8.1.11
Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted Life Years for 29 cancer groups from 2010 to 2019. JAMA Oncology. 2021;8(3):420. doi:10.1001/jamaoncol.2021.6987
Oh HS, Park S, Kim M, et al. Young age and male sex are predictors of Large-Volume central neck lymph node metastasis in clinical N0 papillary thyroid microcarcinomas. Thyroid. 2017;27(10):1285-1290. doi:10.1089/thy.2017.0250
Yan Z, Gang LW, Yan GS, Zhou P. Prediction of the invasiveness of PTMC by a combination of ultrasound and the WNT10A gene. Frontiers in Endocrinology. 2022;13:1026059. doi:10.3389/fendo.2022.1026059
Xu S, Huang H, Huang Y, et al. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis. JAMA Surgery. 2022;158(1):73. doi:10.1001/jamasurg.2022.5781
Konturek A, Barczyński M, Nowak W, Richter P. Prognostic factors in differentiated thyroid cancer—a 20-year surgical outcome study. Langenbeck S Archives of Surgery. 2012;397(5):809-815. doi:10.1007/s00423-011-0899-z
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338. doi:10.1001/jama.2017.2719
Bai Y, Zhou G, Nakamura M, et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Modern Pathology. 2009;22(7):887-894. doi:10.1038/modpathol.2009.38
Elsheikh TM, Thomas M, Brainard J, et al. Papillae, psammoma bodies, and/or many nuclear pseudoinclusions are helpful criteria but should not be required for a definitive cytologic diagnosis of papillary thyroid carcinoma: An institutional experience of 207 cases with surgical follow up. Cancer Cytopathology. 2024;132(6):348-358. doi:10.1002/cncy.22817
Ferreira LB, Gimba E, Vinagre J, Sobrinho-Simões M, Soares P. Molecular aspects of thyroid calcification. International Journal of Molecular Sciences. 2020;21(20):7718. doi:10.3390/ijms21207718
Hunt JL, Barnes EL. Non–Tumor-Associated psammoma bodies in the thyroid. American Journal of Clinical Pathology. 2003;119(1):90-94. doi:10.1309/rwppycbyt2jva023
Montone KT, Baloch ZW, LiVolsi VA. The thyroid hürthle (Oncocytic) cell and its associated pathologic conditions: A surgical pathology and cytopathology review. Archives of Pathology & Laboratory Medicine. 2008;132(8):1241-1250. doi:10.5858/2008-132-1241-tthoca
Wang N, Xu Y, Ge C, Guo R, Guo K. Association of sonographically detected calcification with thyroid carcinoma. Head & Neck. 2006;28(12):1077-1083. doi:10.1002/hed.20481
Das DK. Psammoma body: A product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagnostic Cytopathology. 2009;37(7):534-541. doi:10.1002/dc.21081
Haji BE, Ahmed MS, Prasad A, Omar MS, Das DK. Papillary thyroid carcinoma with an adenoid cystic pattern: Report of a case with fine‐needle aspiration cytology and immunocytochemistry. Diagnostic Cytopathology. 2004;30(6):418-421. doi:10.1002/dc.20063
Kwon HJ, Kim EK, Kwak JY. Value of Additional von Kossa Staining in Thyroid Nodules with “Suspicious for Malignancy” on Cytology. Journal of Korean Thyroid Association. 2015;8(1):81. doi:10.11106/cet.2015.8.1.81
Gallicchio R, Giacomobono S, Capacchione D, et al. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine. 2013;44(2):426-433. doi:10.1007/s12020-013-9935-9
Conzo G, Pasquali D, Bellastella G, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine. 2013;44(2):419-425. doi:10.1007/s12020-013-9877-2
Latrofa F, Ricci D, Grasso L, et al. Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies. The Journal of Clinical Endocrinology & Metabolism. 2007;93(2):591-596. doi:10.1210/jc.2007-1199
Hsieh CJ, Wang PW. Sequential Changes of Serum Antithyroglobulin Antibody Levels Are a Good Predictor of Disease Activity in Thyroglobulin-Negative Patients with Papillary Thyroid Carcinoma. Thyroid. 2013;24(3):488-493. doi:10.1089/thy.2012.0611
Yin N, Sherman SI, Pak Y, et al. The de novo detection of Anti-Thyroglobulin antibodies and differentiated thyroid cancer recurrence. Thyroid. 2020;30(10):1490-1495. doi:10.1089/thy.2019.0791
Copyright (c) 2026 H. A. Aljezan, I. H. Ali, A.A. Mohammed
This work is licensed under a Creative Commons Attribution 4.0 International License.
